All Blogs

Apr 21, 2015

VTE therapeutics & Atrial Fibrillation market was worth USD 4 billion in 2014 and USD 7.86 billion respectively. The VTE therapeutic market is expected to reach USD 5.5 billion by 2018 with a Compound Annual Growth Rate (CAGR) of 8.29% and Atrial Fibrillation market will reach on its peak value USD 13.28 billi...

Apr 17, 2015

Big Pharma Guiding the Stem Cells Future Stem cells (SCs) have been an excitement area of medical research since 1800s. In the mid 1800s it was discovered that cells were basically the building blocks of life and that some cells had the ability to produce other cells and in 1900 scientists had discovered that some...

Apr 13, 2015

PD-1and PDL-1 are the next targeted agents in Oncology. These therapies have the enormous potential to treat cancer and have an excellent response in the increasing number of patients. Many experts say that out of all of the therapies, PD-1/PD-L1 inhibitors look to be the most promising in treating cancer. DelveIns...

Apr 02, 2015

Analyze Anticoagulants Market with DelveInsight Anticoagulants are drugs that are given to prevent blood from clotting or prevent existing clots from getting larger. They can keep harmful clots from forming in heart, veins or arteries. Clots can block blood flow and cause a heart attack or stroke. Until recently, ...

Apr 01, 2015

Antibody Drug Conjugate and Big Pharmaceutical Companies Boom Antibody-drug conjugates is gaining popularity in the Biopharmaceutical industries. As Initial trials with these targeted treatments show success, more companies are looking to produce these drugs. Although antibody-drug conjugates show promise in the d...

Mar 27, 2015

"We used to think that our fate was in our stars, but now we know that, in large measure, our fate is in our genes, "quotes James Watson. This fate that Watson is talking about is contained in our genes, and deals with a new technique, GENE THERAPY. Gene therapy is an innovative way to fix genetic problem from th...

Mar 18, 2015

Launch of DelveInsight’s Antibody-Drug Conjugate Report DelveInsight’s Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-dr...

Mar 13, 2015

Antibody-Drug Conjugates-A Big Boom! Therapeutics developed to create innovative medicines based on the use of new and improved antibodies is the next generation cure for the treatment of various diseases. In past decade, the antibody drug conjugates have emerged out as the active areas of many biopharmaceutical ...

Mar 10, 2015

264 Antibody-Drug Conjugates in Pipeline!!!! Antibody-Drug Conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs by chemical linkers with labile bonds. Billions of dollars are spent on the chemotherapy treatments annually. The ongoing research on this therapy will replace the ch...

Mar 05, 2015

Looking for Passionate Candidates Mail your updated Resume to careers@delveinsight.com  www.delveinsight.com Twitter, Facebook, LinkedIn JOB DESCRIPTION Profile Offered: Associate Analyst Education: M. Pharma/M.tech Biotech Roles and Responsibilities: Conduct market research through primary and secondary sou...